



(Translation)

Minutes of the 2026 Annual General Meeting of Shareholder

Safe Fertility Group Public Company Limited

.....
Date, time, and venue of the Meeting

The 2026 Annual General Meeting of Shareholders (“**the Meeting**”) was convened on Tuesday 28 April 2026, at 10:30 AM, via electronic means (E-Meeting) only according to the Emergency Decree on Electronic Meeting B.E. 2563 (2020). The Meeting was broadcast from the meeting room on the 5th floor, Gaysorn Amarin Building, Ploenchit Road, Lumpini Subdistrict, Pathumwan District, Bangkok

The Meeting convened at 10:30 a.m.

Ms. Thitaree Wongsawangpanit, assigned by the Company to function as the Master of Ceremony of the Meeting (“**the MC**”), welcomed shareholders to the 2026 Annual General Meeting of Shareholders of the Company which the meeting of the Board of Directors resolved to hold via electronic means (E-Meeting) only according to the Emergency Decree on Electronic Meeting B.E. 2563 (2020) and other related laws and regulations. The meeting was held and broadcast live from the Company’s headquarters meeting room via the electronic meeting control system provided by OJ International Co., Ltd.

Then, **the MC** announced the number of shareholders in attendance when the Meeting convened with 10 shareholders attending in person and 24 shareholders attending by proxy, a total of 34 shareholders, representing a total of 249,657,095 shares, equivalent to 82.1381% of all of the Company’s total paid-up ordinary shares 303,947,800 shares. As the number of shareholders exceeded 25 shareholders and the total shares represented more than one-third of the total paid-up ordinary shares, the Meeting was constituted with a quorum in accordance with the law and the Company’s Articles of Association.

The MC introduced the Company’s Independent Directors, Directors, Top Executives and Auditors as follow.

Directors (the directors attending the Meeting accounted for 100%)

1. Mr. Amnuay Preemonwong Independent Director / Chairman of Board of Director / Audit Committee
2. Mr. Jirayut Rungsrithong Independent Director / Chairman of Audit Committee / Nomination and Remuneration Committee
3. Mr. Gran Chayavichitsilp Independent Director / Audit Committee / Chairman of Nomination and Remuneration Committee
4. Mr. Yuttapong Ma Director
5. Mr. Wiwat Quangkananurug Director / Nomination and Remuneration Committee / Chief Executive Officer
6. Mrs. Parinyarat Quangkananurug Director / Managing Director
7. Ms. Chanida Pattanotai Director / Chief Financial Officer

Auditor from PricewaterhouseCoopers ABAS Ltd.

1. Mr. Krit Chatchavalwong
2. Ms. Sanicha Akarakittilap
3. Mr. Prakasit Singkhaw
4. Ms. Phissini Nuamthong

With respect to the documents used for the Meeting today, the Company had published such documents on its website and notified the publication to the Stock Exchange of Thailand on 25 March 2026 so that shareholders have time to study the meeting information in advance.

To ensure that the Meeting was convened smoothly and complies with the principles of good corporate governance, the MC explained about the Meeting's procedures, methods for voting and vote counting and how to express opinions or ask questions as follows.

- The annual general meeting of shareholders has only a normal agenda by considered according to the agenda specified in the meeting invitation letter and there will be no additional agenda items to consider other matters.
- In each agenda, the Company will present information and provide an opportunity for shareholders to ask questions before voting. Shareholders must be present the meeting until the end of the agenda and must vote on each agenda before the closing of voting on such agenda.
- When voting at the Meeting, every shareholder has votes equal to the number of shares which he/she held and register to attend the meeting. One share equals one vote. A shareholder may cast votes of approval or disapproval or abstention on each agenda. If any shareholder has special stakes in any topic, that shareholder will have no right to vote

on that topic except in the case of voting to elect a director. In cases where votes are tied, the Chairman will cast another vote as the deciding vote.

- For shareholders proxy to others to attend the meeting and directed proxies to vote according to shareholders' intentions, the Company recorded the votes of approval or disapproval, or abstention recorded in advance during registration to attend the Meeting according to the stated in the proxy form for voting according to the agenda.
- The method for voting via electronic means
 - Shareholders who wish to vote must be cast in the E-Voting system by clicking on the E-Voting button. For attendees using mobile devices or tablets, please switch from the Zoom program back to the Chrome program to vote in the E-Voting menu.
 - After that, a new window will appear showing various agendas. Shareholders can choose the agenda to vote on and press the voting button as desired. The system will display a total of 3 buttons: "Approval", "Disapproval" and "Abstention". An agenda for acknowledgement will not be able to vote.
 - When you press to select voting, the system will pop up a small window asking to confirm your vote. Press OK to confirm your vote.
 - When you have finished voting, please return to the E-meeting window (Zoom program) to continue viewing the video and audio of the meeting.
 - Voting can be changed until notification of the closing of voting for each agenda. If the agenda has already been closed for voting, shareholders will not be able to vote or change the vote.
 - For voting. The Company will allow shareholders 1 minute time to cast their vote per agenda item.
 - Shareholders who do not vote on any agenda are considered to have voted in approval.
 - Shareholders must be present the meeting until the end of the agenda and must vote on each agenda before the closing of voting on such agenda. In the case that shareholders confirm leaving the meeting or log out without voting in advance before closing voting on any agenda, shareholders' votes will not be counted as a quorum and votes were not counted in that agenda. However, leaving the meeting on any agenda will not deprive the shareholder or proxy of the right to return to the meeting and vote on the next agenda.
- Votes counting for agendas at the 2026 Annual General Meeting of Shareholders are divided into the following 2 types:
 - Agenda item 4, 5, 6 and 8 requires a resolution in approval with a majority vote of the shareholders who attended the Meeting and voted. With respect to Agenda item 6 regarding the election of directors to replace the directors retiring by rotation,

shareholders would be asked to cast their votes for each candidate on an individual basis, in order to be consistent with guidelines on the Annual General Meeting Quality Assessment.

- Agenda item 7 requires a resolution in approval not less than two-thirds (2/3) of the shareholders who attended the Meeting and have the rights to vote.
- Agenda item 1, 2 and 3 no voting due to agenda for acknowledgment.
- To count votes, votes of disapproval or abstention, as well as the votes on invalid ballots (if any) would then be deducted from the total number of votes of the shareholders present at the Meeting, and the remaining numbers would be treated as votes for the approval of that agenda item. Votes cast by proxy grantors in proxy are counted and recorded in advance during registration to attend the Meeting.
- Ballots are invalid in cases where the shareholder appoints a proxy and specifies his votes in advance, but his declared intention is unclear, for example, they specify to vote in more than one box, and the Company is unable to verify such intention to vote of the shareholder.
- The method for asking questions and express opinions via electronics means. Before voting on each agenda, the Chairman will provide an opportunity for shareholders to asking questions and express opinions relevant to such agenda, through the following 2 channels:
Channel 1 Inquiry through Text Message. It can be done as follows
 1. Go to the Q&A menu in the Zoom program to type a message.
 2. Press the Enter button to send a message into the system.
Channel 2: Inquiry through Conversation. It can be done as follows
 1. Go to the Participant menu at the bottom and press the Raise Hand button.
 2. When the MC calls out your name, the staff will turn on the microphone for you to inquire. You must press Unmute and turn on the microphone on your device. In the case that shareholders are unable to speak through the microphone (within 1 minute), please type your questions via the Q&A channel instead so that the MC can read the questions to the meeting on your behalf.
- In asking each question both through typing a message or through conversation, attendees required to provide their name, surname and state whether they are a shareholder or a proxy prior to asking a question in order for the meeting minutes to be recorded completely and accurately. The Company reserves the right to answer only questions related to the agenda that has voting only. As for unrelated questions, they will be answered in Agenda item 9: Other matters.

- The Company provide an opportunity for attendees to submit questions in each agenda. In the event that there are no attendees inquire within 2 minutes, the Company will continue the meeting. If shareholders have additional questions, you can type in your questions via Chat and the staff will read your questions later.
- In case several questions, the Company reserves their right to choose answers as appropriate in order to preserve time. In any case, the Company reserves their right to edit out the visual and audio of any shareholder who asks a question or expresses an opinion which is impolite, defamatory, or violates the laws, or violates other's rights, disrupting the meeting or causing disruption for other attendees.

The Company has sent a link to attend the meeting with a manual for E-Meeting, voting and vote counting methods and how to express opinions or ask questions via email to shareholders. In cases where shareholders encountered problems when accessing the Meeting system or the voting system, please follow meeting instructions that the company has informed. During the meeting, the Company has recorded the meeting in the form of image and video media, including the audio of the meeting of shareholders for publicizing the meeting Through the company's website and other communication channels of the company. If you do not want to publish, please report to email: investorrelations@safefertilitygroup.com.

Mr. Amnuay Premonwong, the Chairman of the Board of Directors, presided as the Chairman of the Meeting (the Chairman) then opened the Meeting and assigned the MC and Miss Tasanun Chuiklom, the Company Secretary, to conduct the Meeting according to the following agendas:

Agenda item 1 **Matters informed by the Chairman**

- None –

Agenda item 2 **To acknowledge the Minutes of the 2025 Annual General Meeting of Shareholders**

The Company Secretary informed the Meeting that the 2025 Annual General Meeting of Shareholders was held on Tuesday, 29 April 2025. The Company completed the minutes of the meeting and submitted them to the Stock Exchange of Thailand within 14 days from the meeting date, as well as published them on the Company's website on Tuesday, 13 May 2025. A copy of the meeting minutes has also been sent to shareholders along with the invitation of the Meeting.

The Board of Directors considered that the recording of the minutes of the 2025 Annual General Meeting of Shareholders has been made correctly and completely, and no shareholders proposed any amendments to the minutes of the meeting.

The proposal for consideration under this agenda is to propose the shareholder's meeting acknowledge the Minutes of the 2025 Annual General Meeting of Shareholders.

Then provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question.

None of shareholder inquiries or express opinions, **the MC** informed that Agenda 2 is an agenda for acknowledgement. Therefore, no voting on this agenda.

The Meeting's Resolution The Shareholder's Meeting acknowledged the Minutes of the 2025 Annual General Meeting of Shareholders.

Agenda item 3 **To acknowledge the Company's operating results for the year 2025**

The Company Secretary informed the Meeting that the Company's operating results and significant changes occurring during the year 2025 had been reported in the Annual Registration Statement / Annual Report 2025 (Form 56-1 One Report), which had been delivered to shareholders in the form of a QR Code together with the invitation of the Meeting and had also been published on the Company's website prior to the Annual General Meeting of Shareholders.

Thereafter, **Mr. Wiwat Quangkananrug, Chief Executive Officer,** and **Ms. Chanida Pattanotai, Chief Financial Officer** were invited to present a summary of the Company's key operations highlights for the year 2025, including a summary of the Company's operating results for the year 2025, to the shareholders for acknowledgement.

Mr. Wiwat Quangkananrug, Chief Executive Officer, and **Ms. Chanida Pattanotai, Chief Financial Officer,** presented a summary of the Company's key operating highlights for the year 2025 as follows:

1. **Advanced Medical Innovation and Technology**

- PGTSeq-A Technology: The Company upgraded its chromosome screening method from conventional NGS to targeted NGS combined with SNIP technology (PGTSeq-A). As a result, the rate of detecting euploid embryos increased from 48.5% to 56.0%, meaning patients had a greater chance of obtaining embryos suitable for implantation. The pregnancy success rate increased from 74.7% to 82.8%, while the miscarriage rate decreased from 21.6% to 16.9%, confirming the effectiveness and efficiency of the PGTSeq-A technology.

- Carrier Screening: Expanded Carrier Screening was introduced to determine whether either parent carries genetic mutations that may cause hereditary diseases in their offspring. It was found that approximately 70–80% of individuals are carriers of certain genetic

conditions, while the probability of both parents carrying and passing the same condition to their child is approximately 3%. This type of screening has become increasingly popular.

2. Data Security and Personal Data Protection

The Company enhanced and upgraded its information security management and personal data protection systems comprehensively, resulting in certifications under ISO/IEC 27001:2022 for Information Security Management Systems and ISO/IEC 27701:2019 for Privacy Information Management Systems. In 2025, the Company reported no incidents of personal data breaches.

3. Anti-Corruption

The Company maintains an anti-corruption policy and is committed to conducting business with transparency, fairness, and accountability throughout all processes. Clear policies and guidelines have been established, with communication and training provided to employees at all levels to ensure strict compliance. The Company regularly assesses fraud risks and has implemented appropriate internal control systems, including continuous monitoring, auditing, and reporting procedures to ensure the effectiveness of such measures. Whistleblowing channels have also been established through the email address: whistleblower@safefertilitygroup.com and the Company's website. No complaints or fraud cases were reported during the year, reflecting the Company's commitment to sustainable good corporate governance.

4. Business Collaboration

The Company has entered into a collaboration with Chiangrai Prachanukroh Hospital to establish a genetics laboratory service under a Private Public Partnership (PPP) model. Operations are expected to commence in the near future.

5. Academic Research

The Company jointly presented an academic research paper with Khon Kaen University entitled "Machine Learning-assisted Embryo Selection: Non-invasive Embryo Ploidy Prediction" in Incheon, South Korea.

In addition, three research studies are scheduled to be presented this year. The first will be presented orally at a genetics conference in Singapore, the second concerns chromosome testing, and the third relates to PGTSeq-A and will be presented in Beijing.

6. Development of Specialized Professionals

The Company continuously supports academic development by sponsoring employee training, providing training programs, and producing ongoing research publications. In 2025, the Company's specialized personnel obtained a total of 49 certificates, representing an increase of 8.89% from 45 certificates in 2024. The Company believes it has distinguished academic achievements.

7. Employee Satisfaction and Engagement

- The Company conducted an employee happiness survey. In 2025, the average employee happiness score increased from 66.84% to 67.71%, which falls within the “happy” category according to the criteria established by the Ministry of Public Health.

- The Company organized health promotion activities by providing exercise support benefits for employees of up to THB 6,000 per year. In the first year, 49.17% of employees participated in the program, and participation is expected to increase in the future.

8. Community Relations

In 2025, the Company conducted 24 Corporate Social Responsibility (CSR) activities, including activities supporting communities and vulnerable groups, healthcare support initiatives, educational and community development activities for remote schools lacking financial resources, and activities promoting medical laboratory and professional knowledge.

9. Environmental Management

The Company implemented energy and resource management measures, including monitoring water and electricity consumption as well as waste management. Electricity consumption increased by 19% and water consumption increased by 12.3% compared to the previous year. The Company plans to strengthen control measures in 2026 in line with its operational growth. Infectious waste decreased by 8.65% compared to the previous year. In addition, the Company measured its greenhouse gas emissions, reporting Scope 1 emissions of 140.25 TonCO₂e and Scope 2 emissions of 603.42 TonCO₂e. The Company will continue to update and report such information to shareholders in 2026.

Regarding the Company’s financial performance for the year 2025, the Company reported consolidated revenue from sales and services of THB 701.92 million, representing a decrease of 15% from the previous year. Such revenue consisted of contributions from three companies as follows: (1) revenue from infertility treatment services provided by SAFE Fertility Group Public Company Limited (“SAFE”) amounting to THB 540.55 million; (2) revenue from embryo and fetal genetic testing services provided by Next Generation Genomic Company Limited (“NGG”) amounting to THB 143.38 million; and (3) revenue from aesthetic and wellness services provided by SAFE Wellness Company Limited (“SWC”) amounting to THB 17.99 million. Revenue contributions from SAFE, NGG, and SWC accounted for 77.01%, 20.43%, and 2.56% of total revenue, respectively.

With respect to profitability, the Company recorded a gross profit of THB 391.20 million, representing a gross profit margin of 55.7%, slightly increased from 55.1% in the previous year. EBITDA amounted to THB 212.31 million, representing an EBITDA margin of 29.5%, which decreased in line with the decline in revenue from sales and services. Net profit amounted to THB 131.10 million, representing a net profit margin of 18.2%.

Regarding the Company's financial position as of 31 December 2025, the Company had total assets of THB 1,923 million, shareholders' equity of THB 1,727 million, and total liabilities of THB 197 million. The Company had no outstanding borrowings from financial institutions.

The Company's return on assets (ROA) was 6.66%, while the return on equity (ROE) was 7.28%.

The Company Secretary informed the Meeting that proposals for consideration under this agenda to propose the shareholder's meeting acknowledge the Company's operating results for the year 2025 as reported.

Then provide an opportunity for shareholders to inquiries or express opinions and asked the MC to explain the process for asking a question. Questions and suggestions that were raised subsequently were summarized as follows.

Ms. Chanathip Wittayakul, a shareholder rights protection volunteer and proxy holder from the Thai Investors Association, submitted the following questions in advance:

1. According to the report on the utilization of IPO proceeds disclosed in the Annual Report (One Report), it was noted that the Company had utilized only approximately THB 6 million for investment in related businesses, compared to the planned budget of more than THB 257 million, while the majority of the funds remained invested in financial assets. She therefore inquired about the Company's criteria for determining the timing of deploying such funds into investments for the expansion of infertility treatment centers in accordance with the original business plan, and whether there were any new projects expected to become clearer within 2026 that could help drive the sustainable growth of the Company's value.

Mr. Wiwat Quangkananrug, Chief Executive Officer, clarified that during 2024 and 2025, the Company had been in discussions regarding several M&A and partnership deals. However, due to the unfavorable economic conditions and valuation differences between buyers and sellers, the transactions had not materialized. For 2026, discussions with one company were currently ongoing and further developments would need to be monitored.

The Company currently held a relatively large amount of cash and therefore received numerous investment proposals, requiring the Company to exercise caution in selecting investment opportunities. He gave an example that, had the Company invested in a certain company, the value of that company had since declined by almost 50%, which would have significantly affected the investment value. Accordingly, the Company remained cautious in utilizing its funds. Nevertheless, he emphasized that the Company was not remaining idle and continued to actively seek investment opportunities.

2. Based on the 2025 financial statements, although the Company had attempted to control administrative expenses, the reduction in such expenses was proportionally smaller than the decline in core revenue (revenue decreased by 15%, while administrative expenses decreased by only 4%). She therefore asked how the Company planned to improve its administrative cost structure to better align with the decline in revenue.

Mr. Wiwat Quangkananrug, Chief Executive Officer, clarified that the issue mainly related to business scale. During the past year, the number of patients and testing volumes had declined, which affected profit margins. However, reducing costs remained difficult because if the Company reduced certain resources, such as personnel, it might not be able to respond promptly when patient numbers and testing volumes recovered. He further stated that, based on current developments, society had become increasingly aware that Thailand had entered a super-aged society, with the fertility rate declining for several years and currently standing at only 0.8%, the lowest level recorded. If such trends continued, Thailand could face significant challenges. He believed that the government would likely introduce policies similar to those implemented in South Korea, Singapore, or China to encourage childbirth. Such government support measures would likely benefit the Company's business. In addition, the Company also provided embryo chromosome testing and non-invasive prenatal testing (NIPT) services, and therefore any increase in pregnancies would likely result in higher demand for NIPT services and generate additional revenue for the Company.

Mr. Ditvaranan Denphaisal, a shareholder, inquired whether the financial assets currently held by the Company were short-term or long-term debt instruments, and how much profit had been generated from such assets in the previous year, including whether such gains were recognized in profit or loss (P&L) or other comprehensive income (OCI).

Ms. Chanida Pattanotai, Chief Financial Officer, clarified that the Company's financial asset investments consisted of money market debt funds with an average maturity of approximately three months. The yield initially ranged between 1.5% and 1.8%, while the current yield was approximately 1.3%. Such returns were recognized in profit or loss (P&L).

Mr. Ditvaranan Denphaisal, a shareholder, asked about the maximum value of the deal currently under discussion.

Mr. Wiwat Quangkananrug, Chief Executive Officer, clarified that the maximum deal value would not exceed THB 500 million.

None of shareholder inquiries or express opinions, **the MC** informed that Agenda item 3 is an agenda for acknowledgement. Therefore, no voting on this agenda.

The Meeting's Resolution The Shareholder's Meeting acknowledged the Company's operating results for the year 2025.

Agenda item 4 **To consider and approve the financial statements for the year ended 31 December 2025**

The Company Secretary invited **Ms. Chanida Pattanotai, Chief Financial Officer**, to explain the Company's financial statements for the year 2025 to shareholders for acknowledgement as follows.

The Company has prepared the financial statements for the year ended 31 December 2025, which have been audited by the auditors of PricewaterhouseCoopers ABAS Ltd.. The auditors expressed an unqualified opinion on the financial statements. In addition, the Audit Committee and the Board of Directors have reviewed and considered the financial statements are of the opinion that the information of the Company and its subsidiaries disclosed therein is accurate, complete, and in compliance with the applicable accounting standards. The summary of the key information is as follows:

Statement of financial position

As previously reported under an earlier agenda item, as of 31 December 2025, the Company had total assets of THB 1,923.35 million, total liabilities of THB 196.85 million, and total shareholders' equity of THB 1,726.50 million.

Statement of Comprehensive Income

The Company recorded revenue from sales and services of THB 701.92 million. After deducting cost of sales and services of THB 310.72 million, the Company reported a gross profit of THB 391.20 million. After deducting selling and administrative expenses of THB 245.13 million, the Company recorded a net profit of THB 128.05 million and a net profit attributable to owners of the parent of THB 131.10 million.

Statement of Cash Flow

The Company generated cash flows from operating activities amounting to THB 107.59 million. Cash flows used in investing activities amounted to THB 653.29 million, mainly attributable to investments in money market. Cash flows used in financing activities amounted to THB 205.18 million, primarily due to dividend payments. As a result, cash decreased by THB 687.87 million. When combined with the beginning cash balance of THB 1,091.12 million, the ending cash balance stood at THB 403.25 million.

The Company Secretary informed the Meeting that proposals for consideration under this agenda to propose the shareholder's meeting approve the financial statements for the year ended 31 December 2025 which have been audited by the auditor and reviewed and approved by the Audit Committee and the Board of Directors.

Then, provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question.

None of shareholders inquired or commented further, and therefore, **the MC** asked the shareholders to cast vote on this agenda item via e-Voting within a timeframe of 1 minute.

This agenda requires a resolution in approval with a majority vote of the shareholders who attended the Meeting and voted.

The Meeting's Resolution The Meeting resolved to approve the financial statements for the year ended 31 December 2024 which have been audited by the auditor, reviewed by reviewed and approved by the Audit Committee and the Board of Directors the statements by the unanimous votes of the shareholders who attended the Meeting and were eligible to vote as follows:

Approved	250,072,596	votes	or	100.0000%
Disapproved	0	votes	or	0.0000%
Voided Ballots	0	votes	or	0.0000%
Total	250,072,596	votes	or	100.0000%
Abstained	-	votes	Not counted as a vote	

Agenda items 5 **To consider and approve the dividend payment for the operation results for the year 2025**

The Company Secretary invited **Ms. Chanida Pattanotai, Chief Financial Officer**, to explain details of dividend payment for the 2025 performance to shareholders as follows.

The Company has a policy to distribute dividends to shareholders at least 50% of the net profit based on the separate financial statements, after deducting corporate income tax, legal reserves, and other reserves (if applicable). The Board of Directors will approve dividend payment by considering various factors, primarily for the benefit of shareholders. Dividend payment will not have a significant impact on the Company's regular operations as the Board of Directors considers appropriate.

From the Company's operating results as shown in the financial statements ending 31 December 2025, the Company had a net profit attributable to owners of the parent for separate financial statement of THB 126.96 million. Therefore, we would like to propose to pay dividends for the operating results from 1 January 2025 to 31 December 2025 at the rate of THB 0.41 per share, totaling THB 124.62 million, representing a dividend payout ratio of 98.16%. The Record Date to determine the name of shareholders who are entitled to receive the dividend has been set on 8 May 2026, and the dividend will be paid on 22 May 2026.

The said dividend payment is in line with the Company's dividend payment policy and does not affect liquidity and the Company's capital structure by taking into account the need for money according to various investment plans

The Company Secretary informed the Meeting that proposals for consideration under this agenda to propose the shareholder's meeting approve to pay dividends for the operating results for the year 2025 at the rate of THB 0.41 per share, totaling THB 124.62 million. The Record Date to determine the name of shareholders who are entitled to receive the dividend has been set on 8 May 2026, and the dividend will be paid on 22 May 2026.

Then, provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question. The questions and comments were summarized as follows:

Mr. Ditvaranan Denphaisal, a shareholder, inquired whether the Company could consider a capital reduction in order to return excess liquidity to shareholders, which he believed would be beneficial to all parties and potentially have a positive impact on the share price. If such action was not feasible, he would like the Company to consider paying dividends at 100% of profit every year.

Ms. Chanida Pattanotai, Chief Financial Officer, clarified that the Company would take the proposal regarding the capital reduction into consideration. Regarding dividend payments, the Company currently pays dividends based on the profits shown in the separate financial statements, and the current dividend payout ratio is 98.16%.

None of shareholders inquired or commented further, and therefore, **the MC** asked the shareholders to cast vote on this agenda item via e-Voting within a timeframe of 1 minute.

This agenda requires a resolution in approval with a majority vote of the shareholders who attended the Meeting and voted.

The Meeting's Resolution The Meeting resolved to approved to pay dividends for the operating results for the year 2025 at the rate of THB 0.41 per share, totaling THB 124.62 million. The Record Date to determine the name of shareholders who are entitled to receive the dividend has been set on 8 May 2026, and the dividend will be paid on 22 May 2026. The shareholders' meeting approved this agenda at the unanimous votes of the shareholders who attended the meeting and voted as follows:

Approved	250,072,596	votes	or	100.0000%
Disapproved	0	votes	or	0.0000%
Voided Ballots	0	votes	or	0.0000%
Total	250,072,596	votes	or	100.0000%
Abstained	-	votes	Not counted as a vote	

Agenda items 6 To consider and approve the appointment of directors in replacement of those who must retire by rotation

The Company Secretary informed the Meeting that the Company's Articles of Association, specify as follows: "At every Annual General Meeting of Shareholders, at least one-third (1/3) of the directors shall retire or the number of directors closest to one-third (1/3) shall retire. The retired directors may be re-elected". At the 2026 Annual General Meeting of Shareholders, 3 directors shall retire by rotation as follow.

- | | |
|-----------------------------------|--|
| 1. Mr. Amnuay Preemonwong | Independent Director /
Chairman of the Board of Director /
Audit Committee |
| 2. Mr. Wiwat Quangkananurug | Director /
Nomination and Remuneration Committee |
| 3. Mrs. Parinyarat Quangkananurug | Director |

In order to comply with the principles of good corporate governance and to ensure transparency, the three directors whose terms expired as listed above were requested to leave the Meeting room until the consideration of this agenda item was completed. As Amnuay Preemnuwong, the Chairman of the Meeting, was required to leave the Meeting, Jirayut Rungsrithong was invited to act as the Chairman of the Meeting for this agenda item.

The Company Secretary informed the Meeting that the Company had provided shareholders with the opportunity to nominate qualified persons for election as directors of the Company in advance during the period from 14 November 2025 to 31 December 2025. The criteria and procedures for such nomination had been published on the Company's website. However, none of the shareholders has nominated any person for consideration for election as a director of the Company.

The Nomination and Remuneration Committee, excluding the nominated directors, has considered and selected qualified individuals to be nominated as directors to replace directors who retire by rotation, based on their knowledge, skills, experience, and expertise that are beneficial and appropriate for the Company's business operations through a process of careful consideration in order to ensure compliance with the criteria for nomination and appointment of the Company's directors. The independence of independent directors is also considered, concerning their abilities to perform their duties, including that such independent directors must be able to provide opinions on an independent basis in accordance with the relevant rules and regulations.

The Nomination and Remuneration Committee, excluding the nominated directors, has considered and concluded that the 3 directors who retire by rotation possess the knowledge, capability, and experience beneficial to the Company's business operations. They have contributed significantly to the Company and have performed their duties effectively as members of the Board of

Directors and various sub-committees. Therefore, it is proposed that the following 3 directors namely: 1) Mr. Amnuay Preemonwong 2) Mr. Wiwat Quangkananurug and 3) Mrs. Parinyarat Quangkananurug to be re-elected as the Company's director for another term of duty, including positions in various sub-committees. In addition, it is proposed that Mr. Amnuay Preemonwong be appointed as an Independent Director.

The Board of Director Meeting, excluding stakeholder directors, has carefully reviewed and approved the proposal of the Nomination and Remuneration Committee

In this regard, the Company has enclosed a brief biography of the nominated persons to the invitation of the Meeting.

The proposal for consideration under this agenda is to propose the shareholders' meeting re-elect the following 3 directors who retire by rotation namely: 1) Mr. Amnuay Preemonwong 2) Mr. Wiwat Quangkananurug and 3) Mrs. Parinyarat Quangkananurug to be the Company's directors for another term, including positions in various sub-committees. In addition, it is proposed that Mr. Amnuay Preemonwong be appointed as an Independent Director.

Then, provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question.

None of shareholders inquired or commented further, and therefore, **the MC** asked the shareholders to cast vote on this agenda item via e-Voting within a timeframe of 1 minute.

This agenda requires a resolution in approval with a majority vote of the shareholders who attended the Meeting and voted.

The Meeting's Resolution The shareholder's meeting resolved to approve the re-election of the 3 directors who retired by rotation namely 1) Mr. Amnuay Preemonwong 2) Mr. Wiwat Quangkananurug and 3) Mrs. Parinyarat Quangkananurug to be the Company's director for another term of duty, including positions in various sub-committees. Mr. Amnuay Preemonwong also resumed his position as an independent director. The voting results were as follows:

- (1) Mr. Amnuay Preemonwong Independent Director /
Chairman of the Board of Director / Audit Committee

The shareholders' meeting approved this agenda at the unanimous votes of the shareholders who attended the meeting and voted as follows:

Approved	249,596,496	votes	or	100.0000%
Disapproved	0	votes	or	0.0000%
Voided Ballots	0	votes	or	0.0000%
Total	249,596,496	votes	or	100.0000%
Abstained	476,100	votes	Not counted as a vote	

(2) Mr. Wiwat Quangkananurug Director / Nomination and Remuneration Committee

The shareholders' meeting approved this agenda at the majority votes of the shareholders who attended the meeting and voted as follows:

Approved	243,712,996	votes	or	97.4569%
Disapproved	6,359,600	votes	or	2.5431%
Voided Ballots	0	votes	or	0.0000%
Total	250,072,596	votes	or	100.0000%
Abstained	0	votes	Not counted as a vote	

(3) Mrs. Parinyarat Quangkananurug Director

The shareholders' meeting approved this agenda at the unanimous votes of the shareholders who attended the meeting and were eligible to vote as follows:

Approved	250,072,596	votes	or	100.0000%
Disapproved	0	votes	or	0.0000%
Voided Ballots	0	votes	or	0.0000%
Total	250,072,596	votes	or	100.0000%
Abstained	0	votes	Not counted as a vote	

After the voting for the appointment of the directors to replace those retiring by rotation was completed, **the MC** invited the newly appointed directors to re-enter the meeting room.

Agenda item 7 **To consider and approve the remuneration of the Board of Directors and Sub-committee for the year 2026**

The Company Secretary informed the Meeting that the Nomination and Remuneration Committee considered the remuneration of the Board of Directors and Sub-committees under the criteria and policy on the determination of remuneration for the Board of Directors and Sub-committees by using important factors such as;

- Appropriate and consistent with the duties and responsibilities of the directors.
- The Company's financial status and performance
- Remuneration rate of companies in the same business group or industry

In 2025, the Company paid remuneration to the Board of Directors and sub-committees totaling THB 1,952,500, which did not exceed the budget amount approved by the 2025 Annual General Meeting of Shareholders.

The Nomination and Remuneration Committee therefore proposes that the remuneration for the Board of Directors and sub-committees for the year 2026 in an amount not exceeding THB 3 million, which is equivalent to that of 2025, with no other forms of benefits.

The Board of Directors has considered and approved the proposal of the Nomination and Remuneration Committee. The details of the remuneration are as follows:

Position	2026 (Proposed year)		2025	
	Monthly remuneration (THB/month)	Meeting Allowance (THB/time)	Monthly remuneration (THB/month)	Meeting Allowance (THB/time)
The Board of Director				
- Chairman	40,000	30,000	40,000	30,000
- Non-executive Director	22,500	20,000	22,500	20,000
- Executive Director	-	20,000	-	20,000
Audit Committee				
- Chairman	-	30,000	-	30,000
- Member	-	25,000	-	25,000
Nominating and Remuneration Committee				
- Chairman	-	15,000	-	15,000
- Member	-	10,000	-	10,000

The proposal for consideration under this agenda is to propose the shareholders' meeting approve the remuneration for the Board of Directors and sub-committees for the year 2026 in an amount not exceeding THB 3 million, which is equivalent to that of 2025, with no other forms of benefits, as detailed in the proposal.

Then, provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question.

None of shareholders inquired or commented further, and therefore, **the MC** asked the shareholders to cast vote on this agenda item via e-Voting within a timeframe of 1 minute.

This agenda requires a resolution in approval not less than two-thirds (2/3) of the shareholders who attended the Meeting and exercised their voting rights.

The Meeting's Resolution The shareholder's meeting resolved to approve the remuneration of the Board of Directors and Sub-committees for the year 2026 in an amount not exceeding THB 3 million, which is equivalent to that of 2025, with no other forms of benefits, as proposed by the Nomination and Remuneration Committee and approved by the Board of Directors. The details are as follows:

Position	2026 (Proposed year)		2025	
	Monthly remuneration (THB/month)	Meeting Allowance (THB/time)	Monthly remuneration (THB/month)	Meeting Allowance (THB/time)
The Board of Director				
- Chairman	40,000	30,000	40,000	30,000
- Non-executive Director	22,500	20,000	22,500	20,000
- Executive Director	-	20,000	-	20,000
Audit Committee				
- Chairman	-	30,000	-	30,000
- Member	-	25,000	-	25,000
Nominating and Remuneration Committee				
- Chairman	-	15,000	-	15,000
- Member	-	10,000	-	10,000

The shareholders' meeting approved this agenda at the unanimous votes of the shareholders who attended the meeting and were eligible to vote as follows:

Approved	250,072,596	votes	or	100.0000%
Disapproved	0	votes	or	0.0000%
Voided Ballots	0	votes	or	0.0000%
Abstained	0	votes	or	0.0000%
Total	250,072,596	votes	or	100.0000%

Agenda item 8 **To consider and approve the appointment of auditor and audit fee for the year 2026**

The Company Secretary informed the Meeting that the Audit Committee has considered the selection of the Company's auditor based on performance, experience, availability of personnel, recognized professional standards, independence of auditor, and the appropriateness of audit fees. The auditors from PricewaterhouseCoopers ABAS Ltd., who have been responsible for auditing and expressing opinions on the Company's financial statements in the previous year, are a

leading international audit firm with a proven track record. The firm demonstrates independence, professional competence, and a strong understanding of the Company's business, along with relevant expertise in auditing the Company. Accordingly, the Audit Committee has agreed to propose to the appointment of auditors from PricewaterhouseCoopers ABAS Ltd. as the Company's and its subsidiaries' auditors for the eighth (8) consecutive fiscal year (2019–2026), with the list of nominated auditors as follows:

- | | | |
|-----------------|---------------|---------------------------|
| 1. Ms. Sanicha | Akarakittilap | CPA Registration No. 8470 |
| 2. Ms. Nopanuch | Apichatsatien | CPA Registration No. 5266 |
| 3. Ms. Yuwanun | Manomivisit | CPA Registration No. 9804 |

Any one of the above auditors shall be appointed to perform the audit and express an opinion on the Company's financial statements. In the event that any of the aforementioned auditors are unable to perform their duties, PricewaterhouseCoopers ABAS Ltd. shall assign another certified public accountant of PricewaterhouseCoopers ABAS Ltd. to act in their stead.

The auditors on the proposed list are qualifications consistent with the regulations of the Securities and Exchange Commission (SEC) and have no relationship and conflict of interest with the Company, its subsidiaries, executives, major shareholders. or persons related to those persons. Therefore, they are independent in performing the audit and expressing their opinion on the financial statement of the Company and its subsidiaries. In addition, none of the three nominated auditors has performed a duty as the Company's auditor for a duration exceeding the number of years stipulated by the relevant notification. The profile The Company has enclosed the profiles of nominated auditors for the year 2026 to the invitation of the Meeting.

And proposed the audit fees for the Company and its subsidiaries for the year 2026, in the total amount of THB 4,650,000, which is equivalent to the audit fees for 2025. Such audit fees exclude non-audit fees and out-of-pocket expenses, which will be charged as necessary on an actual basis, such as travel expenses, telephone charges, postage, and document copying costs. The details comparing the audit fees for the previous year are as follows:

Company	Audit fee (THB)		Non-Audit fee (THB)	
	2026 (proposed year)	2025	2026 (proposed year)	2025
Safe Fertility Group Public Company Limited	2,765,000	2,765,000	-	12,000
Next Generation Genomic Company Limited	1,365,000	1,365,000	-	7,500
Safe Wellness Company Limited	520,000	520,000	-	10,000

Other service fees (Non-Audit fees) for the year 2025 relate to services provided in acting as an observer for the destruction of obsolete/expired inventory.

The Company Secretary informed the Meeting that proposals for consideration under this agenda to propose the shareholders' meeting approve the appointment of auditors from PricewaterhouseCoopers ABAS Company Limited as follows:

- | | | |
|-----------------|---------------|---------------------------|
| 1. Ms. Sanicha | Akarakittilap | CPA Registration No. 8470 |
| 2. Ms. Nopanuch | Apichatsatien | CPA Registration No. 5266 |
| 3. Ms. Yuwanun | Manomivisit | CPA Registration No. 9804 |

And determine an audit and review fee of the financial statements of the Company and its subsidiaries for the year 2025 at total amount is THB 4,650,000, as detailed in the proposal.

Then, provide an opportunity for shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question.

None of shareholders inquired or express opinions, and therefore, **the MC** asked the shareholders to cast vote on this agenda item via e-Voting within a timeframe of 1 minute.

This agenda requires a resolution in approval with a majority vote of the shareholders who attended the Meeting and exercised their voting rights.

The Meeting's Resolution The shareholder's meeting resolved to approve the appointment of auditors from PricewaterhouseCoopers ABAS Company Limited as follows:

- | | | |
|-----------------|---------------|---------------------------|
| 1. Ms. Sanicha | Akarakittilap | CPA Registration No. 8470 |
| 2. Ms. Nopanuch | Apichatsatien | CPA Registration No. 5266 |
| 3. Ms. Yuwanun | Manomivisit | CPA Registration No. 9804 |

And approved the audit and review fees for the financial statements of the Company and its subsidiaries for the year 2025 in the total amount of Baht 4,650,000, as duly considered by the Audit Committee and approved by the Board of Directors.

The shareholders' meeting approved this agenda at the unanimous votes of the shareholders who attended the meeting and were eligible to vote as follows:

Approved	250,072,596	votes	or	100.0000%
Disapproved	0	votes	or	0.0000%
Voided Ballots	0	votes	or	0.0000%
Total	250,072,596	votes	or	100.0000%
Abstained	-	votes	Not counted as a vote	

Agenda item 9 **Other Matters (if any)**

The Company Secretary informed the Meeting that this agenda is set forth in the Shareholders' Meeting for shareholders to ask questions, discuss and/or give recommendations to the Board of Directors and/or the management of the Company (if any). Therefore, no items will be approved and no voting will take place during this agenda.

Then, allowed shareholders to inquiries or express opinions and asked **the MC** to explain the process for asking a question. Questions and suggestions that were raised subsequently were summarized as follows.

None of shareholders inquired or express opinions, **the Chairman** thanked shareholders and every representative for their time at today's meeting and adjourned the meeting.

Meeting adjourned at 12:00 pm.

Signed Chairman of the Meeting
(Mr. Amnuay Preemonwong)

Signed Company Secretary /
(Miss Tasanun Chuiklom) Meeting Recorder